Advanced Filters
noise

gliomas Clinical Trials

A listing of gliomas medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 325 clinical trials
C Carl Koschmann, MD

Combination Therapy for the Treatment of Diffuse Midline Gliomas

This phase II trial determines if the combination of ONC201 with different drugs, panobinostat or paxalisib, is effective for treating participants with diffuse midline gliomas (DMGs). Despite years of research, little to no progress has been made to improve outcomes for participants with DMGs, and there are few treatment options. …

2 - 39 years of age All Phase 2
O Omar H Butt, M.D., Ph.D.

Window of Opportunity Study of DSP-0390 in Gliomas

This study focuses on determining the pharmacokinetic and pharmacodynamic effect of DSP-0390 in brain and blood from patients with IDH-mutant WHO grade II or III glioma undergoing tumor resection. Tissue will be collected during surgical resection. Blood will be drawn at various time points throughout the 2 weeks of treatment. …

18 years of age All Phase N/A
J Junkuan Wang, M.D.

Bevacizumab Neoadjuvant Therapy for New High-grade Gliomas in the Brain

Glioblastoma (GBM) usually grows in a diffuse fashion and infiltrates the surrounding brain. The inability to completely excise the tumor often leads to tumor recurrence within a few months of the initial surgery, which ultimately results in the death of the GBM patient.GBM histologically appears to be a tumor of …

18 years of age All Phase N/A
N Natacha ENTZ WERLE

Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy

Pediatric low-grade glioma (PLGG) is a heterogeneous group of WHO grade I and II brain tumors, associated with a 10-year overall survival of 90%. It is the most common form of primary central nervous system (CNS) tumor arising during childhood, adolescence and young adulthood, accounting for over 30% of CNS …

1 - 25 years of age All Phase 2
A Alexander Dmitriev, MD

Concurrent Fluorescence and Sonographically Guided Eradication of Contrast-enhancing Gliomas and Metastases

Objective of the study is to determine whether combined use of intraoperative fluorescence with 5-aminolevulinic acid (5-ALA) and sonography can achieve higher rate of gross total resection of contrast-enhancing gliomas and brain metastases compared to intraoperative fluorescence with 5-ALA alone.

18 - 79 years of age All Phase N/A
Y Yihui Guan

[18F]BF3-BPA Injection for PET Imaging Study of Gliomas in the Brain

In this clinical study, we proposed to perform [18F]BF3-BPA PET imaging in subjects with gliomas, to observe the binding ability and non-specific binding of the tracer to glioma lesions in vivo, and at the same time to evaluate the effectiveness of [18F]BF3-BPA in the diagnosis and differential diagnosis of glioma, …

18 years of age All Phase N/A
J Jun-ping Zhang

Study of Recombinant Human Endostatin Combined With Temozolomide and Irinotecan in Recurrent Gliomas

Almost all gliomas relapse. After temozolomide rechallenge or combination with irinotecan, the progression-free survival rate at 6 months (PFS-6%) of recurrent glioblastoma was about 21%. After treatment with irinotecan-based chemotherapy regimen, the PFS-6% of recurrent lower-grade gliomas was 40%. The optimal chemotherapeutics of recurrent gliomas has yet to be determined. …

18 - 70 years of age All Phase 2
J Jacques GRILL, MD, PhD

Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0

The BIOMEDE 2.0 study is the second stage of the BIOMEDE multi-arm, multistage rolling programme (adaptive platform protocol). It is a multicenter, randomized open-label phase-3 controlled trial evaluating efficacy of ONC201 in comparison with everolimus (primary objective based on internal comparison) and subsequently to historical controls. Two treatment groups will …

6 years of age All Phase 3
S Site Public Contact

Hyperpolarized Carbon-13 Alpha-ketoglutarate Imaging in IDH Mutant Glioma

This study will investigate the use of hyperpolarized (HP) carbon-13 (13C) alpha-ketoglutarate (aKG) (HP 13C-aKG) to characterize tumor burden in participants with isocitrate dehydrogenase (IDH) mutant glioma.

18 years of age All Phase N/A

The Safety and Effectiveness of NV-A01 in Glioma Patients

The goal of this clinical trial is to learn about the safety and effectiveness of NV-A01 in the treatment of advanced glioma patients. The main questions it aims to answer are: The safety of NV-A01 in the treatment of advanced glioblastoma patients. The effectiveness of NV-A01 in treating patients with …

18 - 65 years of age All Phase 1

Simplify language using AI